Brexit: NOAH’s priorities for the UK animal medicines sector
NOAH has set out the priorities needed to deliver a thriving animal health sector following the UK’s exit from the EU.
Commenting after its Board meeting on 1 November, NOAH Chair Cat Sayer said: “The UK must continue to be a vibrant and innovative animal health market, providing opportunities for animal medicines businesses to thrive.
“We are in a strong position in the UK to be a global centre of excellence for animal medicines, supporting both innovative product developments and a regulatory model to benefit both local and international trade. We need to ensure that our industry’s needs and priorities are included in discussions on how the UK exit develops,” she said.
Following the UK’s exit from the EU, NOAH stresses the need to ensure that measures are in place to facilitate trade and innovation in the animal medicines sector. Future UK regulation of veterinary medicines must incentivise product research and development – an environment where companies are encouraged to do business in the UK.
“The health and welfare of British animals, as well as our public health and food safety need to be safeguarded – our vets and animal keepers need to continue to have access to a wide range of appropriate animal medicines.
“And we must not forget our people. The animal medicines industry has many highly skilled roles. Businesses will continue to need to be able to recruit the best,” said Ms Sayer.
NOAH has formed a Brexit Task Force from members of its Board, covering the breadth of the UK animal medicines sector which is working to identify the risks but also the opportunities offered by the UK post EU Exit for its members. It includes both UK based and global company heads. The Task Force will represent members’ views and drive policy forward at this crucial time.
NOAH is collaborating with partners across the animal health sector, including veterinary, human health, agricultural and pets and engaging with relevant government departments to ensure that veterinary medicines are included in future government industrial strategy.
“In the UK consumers both encourage and expect high standards of animal welfare in food production and pet owners also want prompt and effective care. UK veterinary surgeons and animal owners need access to a full range of medicines and vaccines to protect animal welfare by preventing disease and treating illness effectively,” added Cat.
Notes for editors
For more information please contact Dawn Howard or Alison Glennon at NOAH on 020 8367 3131 or see www.noah.co.uk
1. The National Office of Animal Health represents the UK animal medicines industry. Its aim is to promote the benefits of safe, effective, quality medicines for the health and welfare of all animals.
2. To deliver a thriving animal medicines sector, post-Brexit, NOAH has set out a series of priorities that will:
· Support trade and innovation
· Safeguard animal health and welfare and public health and food safety; ensuring that UK veterinarians and animal keepers continue to have access to a wide range of appropriate veterinary medicines.
· Ensure businesses have access to skilled staff – the right workforce they need
· Incentivise product research and development within a regulatory system which continues to be one of the most stringent in the world – making UK the first choice world-leading regulatory authority
· Encourage companies to do business in the UK as unnecessary regulatory burdens are recognised and removed
· Ensure transitional arrangements to support business continuity post EU Exit are built, utilising links with specialist EU infrastructure where necessary